Ranok Therapeutics (hangzhou) Co., Ltd.
Clinical trials sponsored by Ranok Therapeutics (hangzhou) Co., Ltd., explained in plain language.
-
New targeted pill takes on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis Phase 2 trial is testing an oral drug called RNK08954 in 60 people with metastatic pancreatic cancer that has a specific genetic change (KRAS G12D mutation). The drug is taken daily and aims to slow tumor growth. Researchers will measure how long the cancer stays under contr…
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug targets Hard-to-Treat cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug, RNK08954, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find a safe and effective dose and see if the drug can shrink tumors or slow their growth. About 152 adults who have already tried stan…
Phase: PHASE1, PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC